reports
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a novel drug-device...
Angi Inc. to Announce Q3 2025 Earnings on November 4th and Host Earnin...
Angi Inc. to Announce Q3 2025 Earnings on November 4th and Host Earnings Conference Call on November 5th DENVER, Oct. 08, 2025 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, November 4, 2025, Angi Inc. (NASDAQ: ANGI) will post its third quarter results and publish CEO Jeff Kip's letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, November 5, 2025, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s third quarter results. The live audiocast and repl...
Merit Medical Systems to Announce Third Quarter 2025 Results on Octobe...
Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025 SOUTH JORDAN, Utah, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2025, after the close of the stock market on Thursday, October 30, 2025. Merit plans to hold its investor conference call on the same day (Thursday, October 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). ...
Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with...
Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care SOUTH JORDAN, Utah, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced a significant milestone for breast cancer treatment: SCOUT® Radar Localization use has reached 750,000 patients worldwide.1 This global achievement coincides with Breast Cancer Awareness Month, a time dedicated to educating the public about the ...
Ligand Pharmaceuticals Inc: 1 director
A director at Ligand Pharmaceuticals Inc sold 10,000 shares at 170.809USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Ar...
Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis Expanded indication provides patients with knee osteoarthritis the benefits of Embosphere’s consistent, predictable, and effective clinical results. SOUTH JORDAN, Utah, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that Embosphere® Microspheres are now indicated in the European Union for use in genicular artery embolisation (GAE) to treat patients with knee osteoarthritis (OA). The...
Esquire Financial Holdings Inc: 2 directors
A director at Esquire Financial Holdings Inc sold 9,000 shares at 100.050USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Ligand to Participate in September Investor Conferences
Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand ma...
First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North Americ...
First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North America Registry The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE).The first WRAP North America patient was enrolled at Bluff City Vascular, an interventional nephrology and vascular access center in Memphis, TN. SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the successful enroll...
Ligand Announces Closing of Convertible Senior Notes Offering
Ligand Announces Closing of Convertible Senior Notes Offering JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offering was $460.0 million, which includes the purchase of an additional $60.0 million aggregate principal amount of notes by the initial purchasers pursuant to the full exercise of the initial purchasers’ option to purcha...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offe...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ligand also granted the initial purchasers of the notes (the “initial purchasers...
Ligand Announces Proposed Offering of $400 Million of Convertible Seni...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. Ligand also expec...
Abbvie Inc: 1 director
A director at Abbvie Inc sold 13,295 shares at 198.512USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer ...
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology. The Prelude Wave is the latest innovation in Meri...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidan...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 (previously $6.00 - $6.25) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended Jun...
Angi Inc. Earnings Release and Letter to Shareholders Available on Com...
Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its second quarter financial results and a letter to shareholders from CEO, Jeffrey Kip on the investor relations section of its website at ir.angi.com/quarterly-earnings. As announced previously, Angi Inc. will host a conference call to discuss the company’s second quarter results and to answer questions. The call will be held on Wednesday, August 6, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate...
Merit Medical Reports Second Quarter 2025 Results and Updates Full-Yea...
Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. (“Biolife”), a manufacturer ...
- Jonathan Moreland
Ligand to Report Second Quarter 2025 Financial Results on August 7, 20...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, August 7, 2025 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID ...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 July 2025 in which we reassessed the appropriateness of the ratings in the context of the re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.